Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia

In the absence of head-to-head trials, an indirect-treatment comparison can estimate the treatment effect of tisagenlecleucel in comparison with blinatumomab on rates of complete remission (CR) and overall survival (OS) in patients with relapsed or primary refractory (R/R) acute lymphoblastic leukem...

Descripción completa

Detalles Bibliográficos
Autores principales: Verneris, Michael R., Ma, Qiufei, Zhang, Jie, Keating, Amy, Tiwari, Ranjan, Li, Junlong, Yang, Hongbo, Agarwal, Abhijit, Pacaud, Lida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Health Services and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152996/
https://www.ncbi.nlm.nih.gov/pubmed/34597381
http://dx.doi.org/10.1182/bloodadvances.2020004045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152996/
https://www.ncbi.nlm.nih.gov/pubmed/34597381
http://dx.doi.org/10.1182/bloodadvances.2020004045

Ejemplares similares